The latent threat of tuberculosis
15 August 2012 Feature
Although close to being eradicated in the developed world, TB is still a major problem
TB drug milestone for bedaquiline
3 January 2013
Bedaquiline (sirturo) has become the first drug to be approved in the US for the treatment of multi-drug resistant tuberculosis (TB).
The condition arises when Mycobacterium tuberculosis, the bacteria that cause TB, develop resistance to isoniazid and rifampicin, two key drugs for TB treatment. Bedquiline helps by inhibiting an enzyme the bacteria need to replicate and spread through the body.
The drug has been approved through the ‘accelerated approval’ process, which puts drugs on the market earlier than would otherwise be possible while the companies continue to collect clinical trial data. It was developed by Janssen Therapeutics, a subsidiary of US healthcare giant Johnson & Johnson. The company says bedaquiline is the first TB drug with a new mechanism of action for 40 years.
Related Content
Sensitive TB diagnosis using sugar
6 March 2011 News Archive
A simple sugar can be used to label and monitor tuberculosis in the body and could form the basis of a whole body imaging age...
Most Read
Lab-on-a-chip rises to cola challenge
13 May 2013 Research
'Liquid fingerprinting' can 'taste' the difference between red wines, mineral waters and vodkas
Sugar solution to toxic gold recovery
15 May 2013 Research
The environmental legacy of salvaging gold from electronic waste can be dramatically cut using corn starch instead of cyanide
Most Commented
Congress says US needs a science laureate
14 May 2013 News and Analysis
New legislation proposes the appointment of a public champion for research
US moves in different direction on pesticides
7 May 2013 News and Analysis
While the EU is zeroing in on neonicotinoids as a major cause of bee deaths, the US is looking elsewhere